Signaturefd, LLC Reata Pharmaceuticals Inc Transaction History

Signaturefd, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	BUY	$79.22 - $105.37 $475 - $632	6 Added 6.45%	99 $10,000
Q1 2023 Apr 28, 2023	BUY	$30.85 - $93.17 $246 - $745	8 Added 9.41%	93 $8,000
Q4 2022 Jan 27, 2023	BUY	$22.15 - $42.11 $553 - $1,052	25 Added 41.67%	85 $3,000
Q3 2022 Nov 08, 2022	SELL	$19.41 - $36.49 $1,125 - $2,116	-58 Reduced 49.15%	60 $2,000
Q2 2022 Aug 10, 2022	SELL	$20.71 - $36.5 $3,251 - $5,730	-157 Reduced 57.09%	118 $4,000
Q1 2022 May 02, 2022	BUY	$24.12 - $39.6 $6,633 - $10,890	275 New	275 $9,000
Q4 2021 Jan 25, 2022	SELL	$25.61 - $110.96 $896 - $3,883	-35 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$100.0 - $143.02 $800 - $1,144	-8 Reduced 18.6%	35 $4,000
Q2 2021 Jul 26, 2021	BUY	$78.27 - $151.29 $1,408 - $2,723	18 Added 72.0%	43 $6,000
Q1 2021 Apr 30, 2021	BUY	$94.25 - $132.81 $1,508 - $2,124	16 Added 177.78%	25 $2,000
Q4 2020 Feb 11, 2021	SELL	$102.03 - $184.62 $510 - $923	-5 Reduced 35.71%	9 $1,000
Q3 2020 Nov 03, 2020	BUY	$93.53 - $163.34 $1,309 - $2,286	14 New	14 $1,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

Stay updated on Signaturefd, LLC with notifications on news.